newsonline24

DCI comprises 16 core centers uniting research with every aspect of cardiac practice. The partnership aligns with the launch of DCI’s Center for Cardiovascular Translational Science, a hub dedicated to advancing device testing and simulation in collaboration with academic, clinical, and industry partners—from start-ups to established manufacturers—with a strong emphasis on transcatheter heart valve technologies.

By integrating BDC’s regulatory-grade bench testing capabilities with DCI’s clinical expertise, the two organizations aim to produce evidence-based data that better reflects evolving patient realities—ultimately improving device performance and clinical outcomes.

Bridging Research and Clinical Reality

The Center for Cardiovascular Translational Science focuses on closing the gap between bench and bedside, driving innovation in device design, evaluation, and expanded indications. This includes initiatives such as assessing bioprosthetic valve durability, refining re-intervention techniques, and simulating real-world anatomical challenges.

“We integrate both biological and engineering components to build more clinically representative models that reflect the real challenges our clinical colleagues face every day,” said Stephanie Sellers, PhD, Director of the Centre for Cardiovascular Translational Science. “Our goal is to help our partners develop truly excellent devices. If our models can shift the needle even one percent in terms of clinical outcomes, that’s a meaningful win.”

Achieving Better Clinical Outcomes Through Strategic Collaboration

To support these efforts, BDC Laboratories will equip the center with its HDTi-6000 pulse duplicator—a high-performance, adaptable test platform capable of simulating complex clinical conditions with regulatory-grade precision.

BDC’s active R&D group continuously works alongside clinical, regulatory, and industry experts to ensure its testing systems meet current requirements while anticipating future needs. This includes addressing emerging challenges such as triple-valve testing scenarios and designing diverse artificial root anatomies for more realistic evaluations.

“Innovation in this field often moves faster than the regulatory guidance documents utilized for evaluation,” said Craig Weinberg, PhD, CTO of BDC Laboratories. “Our R&D team works closely with clinical experts, like Stephanie’s group, as well as industry and regulatory leaders, to ensure our testing reflects where the field is heading—while staying aligned with current requirements. Whether our partners are submitting to regulators, exploring novel concepts, or conducting academic research, we’re committed to driving innovation that’s both clinically relevant and regulatory aligned.”

About BDC Laboratories
BDC Laboratories offers testing services and products that aid in the mechanical and functional evaluation of Class II and Class III medical device technologies for regulatory submission. From bioprosthetic valve testing and equipment to silicone vascular models, BDC supports innovation from early R&D through go-to-market.

About the Dilawri Cardiovascular Institute
The Dilawri Cardiovascular Institute is pioneering advanced medical technologies that are reshaping how heart conditions are detected, treated, and managed. Whether you’re a patient seeking better outcomes, a clinician looking for more precise tools, a researcher exploring the future of medicine, or an industry leader driving change—DCI is doing work that matters to you by uniting science, technology, and compassion.

About Tentamus North America
Tentamus North America is part of the Tentamus Group, a global network of highly accredited laboratories offering a wide range of analytical testing and consulting services focused on quality and safety. In North America, Tentamus labs provide expert testing solutions for industries including food and feed, pharmaceuticals, cosmetics, agriculture, and the environment. Committed to scientific excellence and customer service, Tentamus North America partners with clients to ensure product safety, regulatory compliance, and risk mitigation.

For more information on how BDC Laboratories can support your cardiovascular device development, please contact us directly:
BDC Laboratories
Bill Carlson – 303-456-4665 Ext. 1031
bcarlson@bdclabs.com